Jazz Guides to ~$755M IPR&D Charge, ~$11.00 EPS Hit From Actio Deal
JAZZ sits 60% above its 52-week low of $128.8.
Summary
Jazz expects a ~$755 million pre-tax IPR&D charge from the Actio Biosciences acquisition, cutting roughly $11.00 from Q3 2026 GAAP and non-GAAP adjusted EPS. The charge is non-cash and not tax deductible, and the figures are preliminary.
Key Events · Earnings and Guidance · JAZZ
-
Actio Deal Drives $755M IPR&D Charge
Jazz estimates a pre-tax acquired IPR&D charge of approximately $755 million in Q3 2026 related to the Actio Biosciences acquisition, which closed September 15, 2026.
-
EPS Cut by ~$11.00
The charge is not tax deductible and is estimated to reduce both GAAP EPS and non-GAAP adjusted EPS by approximately $11.00 for the third quarter of 2026.
-
Figures Are Preliminary
Q3 results have not been finalized and remain subject to financial statement closing procedures; actual results may differ materially from the estimates.
-
Follows $820M Upfront Deal
The charge traces to the Actio acquisition announced August 10, 2026, with $820 million upfront and up to $500 million in additional consideration.
Analysis · JAZZ · Life Sciences
The accounting consequence of Jazz's $820 million upfront acquisition of Actio Biosciences, closed September 15, now has a number: an estimated ~$755 million pre-tax acquired IPR&D charge in Q3 2026. Because the charge is not tax deductible, it cuts roughly $11.00 from both GAAP and non-GAAP adjusted EPS for the quarter. The cash was already committed at signing, so this is a non-cash earnings event rather than new spending. Still, it lands in the same quarter as the Ziihera first-line approval and the $1.1 billion exchangeable notes offering, and it will make Q3 headline EPS look dramatically worse than the underlying business. The company explicitly flags the figures as preliminary and subject to closing procedures.
How filings like this one have moved
In the 30 days to Oct 27, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAZZ was trading at $205.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.4B. The 52-week trading range was $128.80 to $266.38. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.